Cansino Biologics
Cansino Biologics Inc., commonly referred to as Cansino, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2009, the company has established itself as a leader in the development of innovative vaccines and biologics, with a strong focus on addressing global health challenges. Cansino operates primarily in the fields of vaccine research and development, particularly in the areas of infectious diseases and oncology. The company gained significant recognition for its pioneering work on the Ad5-nCoV vaccine, which was one of the first COVID-19 vaccines to receive emergency use authorisation. Cansino's unique adenoviral vector platform sets it apart in the industry, enabling rapid development and deployment of vaccines. With a robust pipeline and strategic partnerships, Cansino Biologics continues to solidify its position as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Cansino Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cansino Biologics's score of 34 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cansino Biologics's reported carbon emissions
In 2023, Cansino Biologics reported total carbon emissions of approximately 37,294,900 kg CO2e, with Scope 1 emissions at about 2,335,900 kg CO2e and Scope 2 emissions at approximately 19,689,150 kg CO2e. The company has shown a significant reduction in emissions over the years, with a notable decrease from 35,159,360 kg CO2e in 2021 to the current figure. In 2022, Cansino's emissions were approximately 30,517,250 kg CO2e, indicating a trend towards lower emissions. The company has disclosed emissions data for Scope 1 and Scope 2, but there is no available data for Scope 3 emissions. Despite the reductions, Cansino Biologics has not set specific reduction targets or climate pledges, which may limit their long-term sustainability commitments. The company continues to focus on improving its emissions per floor area, which was reported at about 420 kg CO2e per square metre in 2023. Overall, while Cansino Biologics has made strides in reducing its carbon footprint, the absence of formal reduction targets suggests an opportunity for further commitment to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,609,750 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 10,386,950 | 000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000 | 000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cansino Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
